BIOMAT Database Logo BIOMAT Database Logo

CLINICAL AND SEROLOGICAL OBSERVATIONS ON THE CHILDREN GIVEN ATTENUATED MEASLES VACCINE. 1963

M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003168 Complement Fixation Tests Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1. Complement Absorption Test, Conglutinating,Conglutination Reaction,Conglutinating Complement Absorption Test,Complement Fixation Test,Conglutination Reactions,Fixation Test, Complement,Fixation Tests, Complement,Reaction, Conglutination,Reactions, Conglutination,Test, Complement Fixation,Tests, Complement Fixation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
[Clinical and serological studies on a further attenuated live measles virus AIK vaccine].
April 1973, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
Studies on further attenuated live measles vaccine. IV. Clinical and serological evaluation of a clone of CAM-CEF measles vaccine virus.
September 1970, Biken journal,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
[Electroencephalographic and clinical observations in active measles vaccination with attenuated live vaccine].
January 1966, Das Deutsche Gesundheitswesen,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
[Living attenuated measles-virus vaccine. IV. Serological response of children before and after immunization with a living measles-virus vaccine].
January 1965, Nihon Ika Daigaku zasshi,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
Attenuated measles vaccine in Nigerian children.
March 1962, American journal of diseases of children (1960),
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
[Clinical and epidemiological observations on children inoculated with measles tissue vaccine].
June 1960, Pediatriia,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
Measles immune globulin. Proposed standard dose given with liver attenuated measles virus vaccine.
January 1968, JAMA,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
[Clinical and serological studies with a live further attenuated measles vaccine (Moraten) in Chile].
January 1970, Revista medica de Chile,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
Reactions to live measles vaccine in children previously given killed measles vaccine.
November 1967, The Medical journal of Australia,
M ARAI, and M NAKAMURA, and T AKAMATSU, and M KIMURA, and T KITAYAMA, and G KOIDE
Studies on further attenuated liver measles vaccine. VI. Clinical and serological follow-up one year after vaccination.
September 1971, Biken journal,
Copied contents to your clipboard!